Cystinosis: Therapy adherence and metabolic monitoring in patients treated with immediate-release cysteamine
Background: Cystinosis is a metabolic disease caused by intracellular accumulation of cystine within lysosomes. Development of symptoms can be delayed significantly by a life-long therapy with cysteamine, a drug that enters the lysosome and reacts with cystine thereby enabling its export from the or...
Main Authors: | Simone Linden, Sabrina Klank, Erik Harms, Marianne Grüneberg, Julien H. Park, Thorsten Marquardt |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Molecular Genetics and Metabolism Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2214426920300665 |
Similar Items
-
A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis
by: Christina van Stein, et al.
Published: (2021-09-01) -
Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients
by: Sabrina Klank, et al.
Published: (2023-06-01) -
Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to “A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis”)
by: Craig B. Langman
Published: (2023-06-01) -
The Pitfall of White Blood Cell Cystine Measurement to Diagnose Juvenile Cystinosis
by: Tjessa Bondue, et al.
Published: (2023-01-01) -
Endocrine complications during and after adolescence in a patient with cystinosis
by: Moon Bae Ahn, et al.
Published: (2016-09-01)